Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Biomarker studies for potentially predicting response to nivolumab in patients with unresectable or recurrent non-small cell lung cancer

Trial Profile

Biomarker studies for potentially predicting response to nivolumab in patients with unresectable or recurrent non-small cell lung cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 16 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 10 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top